There are currently 1519 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Glucagon-like Peptide-1 in Type 1 Diabetes
NCT04355832
Recruiting
The hypotheses to be tested in this application is: GLP-1 will acutely protect arterial endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated hypoglycemia in T1DM.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
11/01/2024
Locations: University of Maryland, Baltimore, Maryland
Conditions: Type1 Diabetes Mellitus
Register for Updates
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
NCT04797286
Recruiting
This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Johns Hopkins, Baltimore, Maryland
Conditions: Scleroderma, Mildly Elevated Pulmonary Pressures
Register for Updates
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
NCT05682443
Recruiting
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Johns Hopkins University Medical Center - 1627, Baltimore, Maryland
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Multidisciplinary Approach to Reduce Cardiovascular Health Disparities
NCT06168968
Recruiting
The goal of this observational study is to investigate the potential differences in thrombogenicity between black and white patients admitted with atherothrombotic events including acute coronary syndrome, multi-vessel coronary disease, and ischemic stroke. Participants will engage in laboratory testing and health outcome assessments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland
Conditions: Acute Coronary Syndrome, Multi Vessel Coronary Artery Disease, Ischemic Stroke
Register for Updates
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
NCT06311708
Recruiting
This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless of interest in or eligibility for gene therapy.
Gender:
ALL
Ages:
Between 14 years and 65 years
Trial Updated:
10/30/2024
Locations: John Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
Register for Updates
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
NCT05450965
Recruiting
This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme that is over-expressed in many cancer cells and is involved in cellular repair.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Small-cell Lung Cancer, Small Cell Lung Carcinoma
Register for Updates
Platelet-Directed Whole Blood Transfusion Strategy for Malaria
NCT05711485
Recruiting
Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.
Gender:
ALL
Ages:
Between 6 months and 59 months
Trial Updated:
10/29/2024
Locations: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
Conditions: Severe Malaria, Thrombocytopenia
Register for Updates
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
NCT06014255
Recruiting
This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical prostatectomy or standard of care arms.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Prostate Cancer
Register for Updates
Developing a Clinical Outcome Assessment for Opioid Craving
NCT05109429
Recruiting
The purpose of this study is to collect information about opioid craving so that the investigators can develop an opioid craving assessment to improve treatments for individuals with opioid use disorder. To collect this information, the investigators are recruiting individuals in treatment for opioid use disorder who will complete cue-induced opioid craving tasks where these individuals will: (1) look at pictures of neutral objects and touch neutral objects (e.g., water bottles or flashlights),... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Behavioral Pharmacology Research Unit, Baltimore, Maryland
Conditions: Opioid Craving, Opioid Use Disorder, Measure Development
Register for Updates
Psilocybin in Chronic Low Back Pain and Depression
NCT06355414
Recruiting
This study seeks to provide insight on psilocybin's effects on mechanisms of chronic pain among patients with co-morbid chronic low back pain and depression (CLBP+D). Participants will receive either a single high-dose of psilocybin (25mg absolute dose) or methylphenidate (40mg absolute dose). Participants will be asked to complete assessments of pain, depressive symptoms, and more general questionnaires regarding the participants experiences during the experimental sessions and the associated... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
10/24/2024
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Chronic Low-back Pain, Depression
Register for Updates
Use Of Gigstride Device In Patients With Lower Extremity Deficit
NCT06548087
Recruiting
For patients with lower extremity deficits, the investigator(s) would like to assess implementing use of Gigstride ambulatory device to assess the following: * Patient satisfaction with use of ambulatory device * Effects of Gigstride device utilization on kinetics, biomechanics * Effects of Gigstride device utilization on walking speed, stair speed, stability
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Ambulation Difficulty, Lower Extremity Problem
Register for Updates
Trial of Therapeutic Hypothermia in Patients With ARDS
NCT04545424
Recruiting
Acute Respiratory Distress Syndrome (ARDS) is a serious condition that occurs as a complication of medical and surgical diseases, has a mortality of \~40%, and has no known treatment other than optimization of support. Data from basic research, animal models, and retrospective studies, case series, and small prospective studies suggest that therapeutic hypothermia (TH) similar to that used for cardiac arrest may be lung protective in patients with ARDS; however, shivering is a major complication... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/23/2024
Locations: University of Maryland Medical Center, Baltimore, Maryland +1 locations
Conditions: Respiratory Distress Syndrome, Adult
Register for Updates